Multiple Sclerosis Therapeutics Market Share

Statistics for the 2023 & 2024 Multiple Sclerosis Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Multiple Sclerosis Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

INSTANT ACCESS

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Multiple Sclerosis Therapeutics Industry

The multiple sclerosis therapeutics market is moderately competitive, as there are few players in this market. These companies are the big pharmaceutical companies focusing on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, it is believed that more companies may enter the market studied in the future, and the competition may increase. A few of the major companies currently dominating the market are Biogen Inc., Novartis AG, Merck KGaA, Sanofi, and Acorda Therapeutics, Inc., among others.

Multiple Sclerosis Therapeutics Market Leaders

  1. Biogen Inc.

  2. Novartis AG

  3. Merck KGaA

  4. Sanofi S. A.

  5. Acorda Therapeutics, Inc.

*Disclaimer: Major Players sorted in no particular order

Multiple Sclerosis Therapeutics Market Concentration

Multiple Sclerosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)